Ovarian cancer: Strategies for overcoming resistance to chemotherapy

被引：991

作者：

Agarwal, R ^{[1
]}

Kaye, SB ^{[1
]}

机构：

[1] Inst Canc Res, Med Sect, Sutton SM2 5NG, Surrey, England

来源：

NATURE REVIEWS CANCER | 2003年 / 3卷 / 07期

关键词：

D O I：

10.1038/nrc1123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.

引用

页码：502 / 516

页数：15

共 168 条

[1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].

Aabo, K ;

Adams, M ;

Adnitt, P ;

Alberts, DS ;

Athanazziou, A ;

Barley, V ;

Bell, DR ;

Bianchi, U ;

Bolis, G ;

Brady, MF ;

Brodovsky, HS ;

Bruckner, H ;

Buyse, M ;

Canetta, R ;

Chylak, V ;

Cohen, CJ ;

Colombo, N ;

Conte, PF ;

Crowther, D ;

Edmonson, JH ;

Gennatas, C ;

Gilbey, E ;

Gore, M ;

Guthrie, D ;

Kaye, SB ;

Laing, AH ;

Landoni, F ;

Leonard, RC ;

Lewis, C ;

Liu, PY ;

Mangioni, C ;

Marsoni, S ;

Meerpohl, H ;

Omura, GA ;

Parmar, MKB ;

Pater, J ;

Pecorelli, S ;

Presti, M ;

Sauerbrei, W ;

Skarlos, DV ;

Smalley, RV ;

Solomon, HJ ;

Stewart, LA ;

Sturgeon, JFG ;

Tattersall, MHN ;

Wharton, JT ;

Huinink, WWT ;

Tomirotti, M ;

Torri, W ;

Trope, C .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487

[2] Proteasome inhibition: a novel approach to cancer therapy [J].

Adams, J .

TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54

[3]

AGARWAL M, 2002, P AN M AM SOC CLIN, V21, pA410

[4]

AGHAJANIAN C, 2000, P AN M AM SOC CLIN, V19, pA736

[5]

Agus DB, 2000, SEMIN ONCOL, V27, P53

[6] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[7] RAPID EMERGENCE OF ACQUIRED CIS-DIAMMINEDICHLOROPLATINUM(II) RESISTANCE IN AN INVIVO MODEL OF HUMAN OVARIAN-CARCINOMA [J].

ANDREWS, PA ;

JONES, JA ;

VARKI, NM ;

HOWELL, SB .

CANCER COMMUNICATIONS-US, 1990, 2 (02) :93-100

[8]

[Anonymous], SEMIN ONCOL

[9]

APPLETON K, 2003, P AM ASS CAN RES, V44, pA4023

[10]

ARMSTRONG DK, 2002, P AN M AM SOC CLIN, V21, pA803

← 1 2 3 4 5 6 7 8 9 10 →